Skip to search formSkip to main contentSkip to account menu

insulin aspart, insulin aspart protamine drug combination 30:70

Known as: BIAsp 30, biphasic insulin aspart 30:70, biphasic insulin aspart 30 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Biphasic InsulinsHypoglycemic AgentsInsulin Aspartinsulin, isophane

Narrower (1)

NovoLog Mix 70/30

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes
Aim: This 3-month study compared the effect on overall glycemic control of adding biphasic insulin aspart 30 (BIAsp30) and… 
2009
2009
A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
The purpose of this study was to evaluate pharmacokinetic and pharmacodynamic profiles of pure insulin aspart and three different… 
2007
2007
Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes
Aim:  To evaluate the efficacy and safety of adding biphasic insulin aspart 30 (BIAsp30; NovoMix® 30) to existing oral… 
2005
2005
Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study).
OBJECTIVE Major advantages of modern insulin regimens containing premixed insulin analogues in comparison to traditional insulin… 
2005
2005
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week…
2005
2005
Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
BACKGROUND Premixed insulin analogues reduce postprandial hyperglycemia in patients with Type 2 diabetes in comparison to… 
2005
2005
The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
AIMS To evaluate the pharmacokinetic and pharmacodynamic properties of two different formulations of premixed analogue (mixed… 
2005
2005
Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double‐blinded crossover study
Aims  To compare pharmacokinetic characteristics of two biphasic insulin aspart (BIAsp) formulations: BIAsp30 and BIAsp70 (30… 
Highly Cited
2003
Highly Cited
2003
Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes
Objective:  Biphasic insulin aspart 30 (BIAsp30) is a dual release formulation, containing 30% soluble and 70% protamine… 
2003
2003
Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)